#BEGIN_DRUGCARD DB01606

# AHFS_Codes:
Not Available

# ATC_Codes:
J01CG02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Tazocin (Tazobactam + Piperacillin)
Zosyn (Tazobactam + Piperacillin)

# Brand_Names:
Not Available

# CAS_Registry_Number:
89786-04-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C10H12N4O5S

# Chemical_IUPAC_Name:
(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2170795

# Description:
Tazobactam is a antibacterial penicillin derivative which inhibits the action of bacterial beta-lactamases.

# Dosage_Forms:
Not Available

# Drug_Category:
Enzyme Inhibitors

# Drug_Interactions:
Demeclocycline	Possible antagonism of action
Doxycycline	Possible antagonism of action
Ethinyl Estradiol	This anti-infectious agent could decrease the effect of the oral contraceptive
Minocycline	Possible antagonism of action
Tetracycline	Possible antagonism of action

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Tazobactam

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1

# InChI_Key:
InChIKey=LPQZKKCYTLCDGQ-WEDXCCLWSA-N

# Indication:
Used in combination with piperacillin to broaden the spectrum of piperacillin antibacterial action.

# KEGG_Compound_ID:
C07771

# KEGG_Drug_ID:
D00660

# LIMS_Drug_ID:
1606

# Mechanism_Of_Action:
Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express beta-lactamase and would normally degrade piperacillin.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
300.291

# Molecular_Weight_Mono:
300.052840204

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
1VM1

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164764504

# Pharmacology:
Tazobactam is a compound which inhibits the action of bacterial beta-lactamases. It is added to the extended spectrum beta-lactam antibiotic piperacillin.

# Predicted_LogP_Hydrophobicity:
-1.8

# Predicted_LogS:
-1.5

# Predicted_Water_Solubility:
9.59e+00 g/l

# Primary_Accession_No:
DB01606

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
123630

# PubChem_Substance_ID:
46508088

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03012

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:19 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Tazobactam

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AF148850

# Drug_Target_1_GenBank_ID_Protein:
5002312

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
bla

# Drug_Target_1_Gene_Sequence:
>861 bp
ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACAC
GCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTA
GGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAA
CGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTG
GATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGAC
TACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCC
GCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGC
CCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGC
TGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCC
AGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAA
CGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTG
CTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGG
ATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGG
GATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTG
ATCGAGCACTGGCAACGCTAA

# Drug_Target_1_General_Function:
Defense mechanisms

# Drug_Target_1_General_References:
3260490	Barthelemy M, Peduzzi J, Labia R: Complete amino acid sequence of p453-plasmid-mediated PIT-2 beta-lactamase (SHV-1). Biochem J. 1988 Apr 1;251(1):73-9.
3497152	Barthelemy M, Peduzzi J, Labia R: N-terminal amino acid sequence of PIT-2 beta-lactamase (SHV-1) J Antimicrob Chemother. 1987 Jun;19(6):839-41.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3687

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
31224

# Drug_Target_1_Name:
Beta-lactamase SHV-1 precursor

# Drug_Target_1_Number_of_Residues:
286

# Drug_Target_1_PDB_ID:
1Q2P

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_1_Protein_Sequence:
>Beta-lactamase SHV-1 precursor
MRYIRLCIISLLATLPLAVHASPQPLEQIKLSESQLSGRVGMIEMDLASGRTLTAWRADE
RFPMMSTFKVVLCGAVLARVDAGDEQLERKIHYRQQDLVDYSPVSEKHLADGMTVGELCA
AAITMSDNSAANLLLATVGGPAGLTAFLRQIGDNVTRLDRWETELNEALPGDARDTTTPA
SMAATLRKLLTSQRLSARSQRQLLQWMVDDRVAGPLIRSVLPAGWFIADKTGAGERGARG
IVALLGPNNKAERIVVIYLRDTPASMAERNQQIAGIGAALIEHWQR

# Drug_Target_1_Reaction:
A beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_1_Signals:
1-21

# Drug_Target_1_Specific_Function:
A beta-lactam + H(2)O = a substituted beta- amino acid

# Drug_Target_1_SwissProt_ID:
P0AD63

# Drug_Target_1_SwissProt_Name:
BLA1_ECOLX

# Drug_Target_1_Synonyms:
EC 3.5.2.6
PIT-2

# Drug_Target_1_Theoretical_pI:
8.08

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10511459	Yang Y, Rasmussen BA, Shlaes DM: Class A beta-lactamases--enzyme-inhibitor interactions and resistance. Pharmacol Ther. 1999 Aug;83(2):141-51.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AL513383

# Drug_Target_2_GenBank_ID_Protein:
16505919

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
bla

# Drug_Target_2_Gene_Sequence:
>861 bp
ATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCT
GTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCA
CGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCC
GAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCC
CGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTG
GTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTA
TGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATC
GGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTT
GATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATG
CCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCT
TCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGC
TCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCT
CGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTAC
ACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCC
TCACTGATTAAGCATTGGTAA

# Drug_Target_2_General_Function:
Defense mechanisms and antibioitic degradation

# Drug_Target_2_General_References:
11677608	Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, Wain J, Churcher C, Mungall KL, Bentley SD, Holden MT, Sebaihia M, Baker S, Basham D, Brooks K, Chillingworth T, Connerton P, Cronin A, Davis P, Davies RM, Dowd L, White N, Farrar J, Feltwell T, Hamlin N, Haque A, Hien TT, Holroyd S, Jagels K, Krogh A, Larsen TS, Leather S, Moule S, O'Gaora P, Parry C, Quail M, Rutherford K, Simmonds M, Skelton J, Stevens K, Whitehead S, Barrell BG: Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature. 2001 Oct 25;413(6858):848-52.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2858

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
31516

# Drug_Target_2_Name:
Beta-lactamase TEM

# Drug_Target_2_Number_of_Residues:
286

# Drug_Target_2_PDB_ID:
1S0W

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_2_Protein_Sequence:
>Beta-lactamase TEM precursor
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVEYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAGERGS
RGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW

# Drug_Target_2_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_2_Signals:
1-23

# Drug_Target_2_Specific_Function:
TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins

# Drug_Target_2_SwissProt_ID:
P62594

# Drug_Target_2_SwissProt_Name:
BLAT_SALTI

# Drug_Target_2_Synonyms:
Beta-lactamase TEM precursor
EC 3.5.2.6
Penicillinase

# Drug_Target_2_Theoretical_pI:
5.92

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01606
